F S&P 500
5,512.00 +21.00 (+0.38%) F Dow Jones
38,892.00 +33.00 (+0.08%) F Nasdaq
20,039.00 +119.75 (+0.60%) E-mini Russell 2000 Index Futur
2,056.00 +6.70 (+0.33%) Petróleo
81.60 +0.03 (+0.04%) Oro
2,353.10 +6.20 (+0.26%)
TELA Bio, Inc. (TELA)
Fuera de horario:
TELA Bio, Inc.
1 Great Valley Parkway
Suite 24
Malvern, PA 19355
United States
484 320 2930
https://www.telabio.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 227
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Antony Koblish | Co-founder, President, CEO & Director | 1.03M | N/D | 1966 |
| Mr. Roberto E. Cuca J.D. | CFO & COO | 674.78k | N/D | 1968 |
| Mr. Paul Talmo | Chief Technology Officer | 595.67k | N/D | 1972 |
| Ms. Megan Smeykal | VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer | N/D | N/D | 1976 |
| Mr. D. Taylor Ocasio | General Counsel & Corporate Secretary | N/D | N/D | N/D |
| Ms. Jennifer Lou Armstrong | Senior Vice President of Human Resources | N/D | N/D | 1970 |
| Mr. Gregory A. Firestone | Chief Commercial Officer | N/D | N/D | 1959 |
| Mr. Michael Leonard | Senior Vice President of Technical Operations | N/D | N/D | N/D |
| Mr. Peter C. Murphy | Chief Commercial Officer | 542.34k | N/D | 1973 |
| Louisa Smith | Investor Relations Contact Officer | N/D | N/D | N/D |
Descripción
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de TELA Bio, Inc. a partir del 1 de junio de 2024 es 9. Las puntuaciones principales son Auditoría: 4; Junta: 5; Derechos del accionista: 8; Compensación: 10.
